Eikon Therapeutics Announces Seven Abstracts Accepted for Presentation at the 2026 European Society of Medical Oncology (ESMO) Congress
Eikon Therapeutics announced acceptance of seven abstracts for presentation at the 2026 European Society of Medical Oncology (ESMO) Congress. These presentations include updates on multiple clinical trials evaluating their novel oncology drug candidates, including TLR7/8 dual agonist EIK1001 for advanced NSCLC, selective PARP1 inhibitors EIK1003 an…